Precision AQ Welcomes Three Oncology Experts to Enhance Team
Precision AQ Enhances Access Experience Team with Oncology Experts
In a significant move to strengthen its capabilities in oncology, Precision AQ has welcomed three renowned specialists to its Access Experience Team (AET). This decision aligns with the company's vision of improving patient access to critical therapies and reflects its commitment to adapting to the ever-evolving healthcare landscape.
Meet the New Additions to the AET
The expanded AET now includes Shraddha Kansagra, PharmD, BCOP, Angelica Norrell, PharmD, BCOP, CSP, and Courtney Patterson, PharmD, MBA. Each brings a wealth of experience and expertise in oncology, ready to enhance Precision AQ's reputation as a leader in life sciences commercialization.
Background of Shraddha Kansagra
Shraddha Kansagra joins as Vice President, Clinical Oncology Solutions. Previously a clinical pharmacy specialist at a prominent academic institution, she focused on optimizing chemotherapy and immunotherapy treatment workflows. Her experience contributes significantly to Precision AQ's efforts in streamlining patient care and enhancing access to cutting-edge therapies.
Angelica Norrell's Role
As Senior Director of AET, Angelica Norrell transitions from a senior director position in a leading healthcare organization, where she oversaw oncology product management. Her expertise spans both payer and provider landscapes, positioning the AET to better navigate the complexities of oncology care and reimbursement.
Insights from Courtney Patterson
Courtney Patterson brings her extensive knowledge from her prior role as System Director of Oncology Pharmacy Services to her new position as Vice President, Clinical Oncology Solutions. Her background includes managing a network of oncology clinics and improving pharmacy operations within healthcare systems, ensuring patients receive optimal care.
Strengthening Oncology Expertise
The addition of these oncology experts solidifies Precision AQ's AET, which now includes several board-certified oncology pharmacists and leaders with vast experience across various healthcare settings. Their combined expertise aims to provide insightful strategies that can help life sciences companies address payer challenges effectively.
With oncology access decisions becoming increasingly multifaceted, the experience of this team will play a vital role in guiding clients through policy changes and navigating operational hurdles that impact access to therapies. Precision AQ is positioned to leverage its advisory capabilities, directly benefiting clients and, ultimately, patients.
A Comprehensive Strategic Approach
The AET's enhancements allow Precision AQ to delve deeper into coverage and reimbursement trends, crafting value-based agreements that facilitate access to innovative treatments. The team will also focus on transforming market insights into actionable strategies, ensuring that cancer patients receive the therapies they require without unnecessary delays.
About Precision AQ's Access Experience Team
Founded in 2009, the Access Experience Team at Precision AQ consists of over 25 former decision-makers in the healthcare access landscape. By bridging gaps between payers and life sciences, the AET provides invaluable insights into overcoming reimbursement barriers and adapting to changing policies. This integration into Precision AQ's operations underscores the importance of actionable strategies that facilitate patient access.
About Precision AQ
As a key player within Precision Medicine Group, Precision AQ assists life sciences companies throughout their commercialization journey. With a multifaceted approach that combines strategic guidance and expert analysis, the organization is committed to ensuring that patients have access to groundbreaking therapies. The company offers a broad spectrum of services, including market access strategies, health economics research, and more, positioning itself as a vital partner in the healthcare industry.
Frequently Asked Questions
What is the purpose of expanding the Access Experience Team?
The expansion aims to enhance expertise in oncology, helping clients navigate complex reimbursement landscapes and improve patient access to therapies.
Who are the notable new members of the AET?
The new members include Shraddha Kansagra, Angelica Norrell, and Courtney Patterson, who bring extensive experience in oncology and pharmacy.
How does Precision AQ support life sciences companies?
Precision AQ provides strategic insights, guidance on payer practices, and comprehensive services aimed at improving patient access to life-changing therapies.
Why is oncology access becoming more complex?
Oncology access involves multiple stakeholders, including payers and providers, making the decision-making process intricate and requiring specialized knowledge.
What role does the AET play in Precision AQ's strategy?
The AET informs clients about market access insights, helping them devise actionable strategies to enhance therapy availability for patients.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.